Mirum Q3 revenue $133M, up 47% YoY; lifts FY guidance to $500-510M

Mirum Pharmaceuticals, Inc.

2025-Q3 EPS reported -$0.35 revenue$372,380,000

Q3 2025 total revenue $133.0M vs $90.4M in Q3 2024; LIVMARLI sales $92.2M (+56% YoY).
Bile Acid Medicines net sales $40.8M, up 31% YoY; cash and investments $378M.
Volixibat VISTAS (PSC) enrollment complete; topline data expected Q2 2026.
Volixibat VANTAGE (PBC) and LIVMARLI EXPAND enrollment expected 2026; topline H1 2027.
Phase 2 study of MRM-3379 for Fragile X Syndrome initiated.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.